AditxtADTX -6.82% 14-Day RSI is 13.94 as of Jul. 11, 2026. The stock has 4 warning signs investors should review. Among 1,420 Biotechnology companies, Aditxt ranks better than 99.3% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-11), Aditxt's 14-Day RSI is 13.94.
The industry rank for Aditxt's 14-Day RSI or its related term are showing as below:
ADTX's 14-Day RSI is ranked better than 99.3% of 1420
companies
in the Biotechnology industry
Industry Median: 48.885
vs ADTX: 13.94
Aditxt (OTCPK:ADTX) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Aditxt 14-Day RSI Related Terms
ADTX vs AAGH, PKTX, VBIO: 14-Day RSI Comparison
For the Biotechnology subindustry, Aditxt's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aditxt 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aditxt's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Aditxt's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aditxt (ADTX) has a 14-Day RSI of 13.94 as of Jul. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Aditxt and its competitors. According to the industry distribution chart, Aditxt ranks #10 out of 1420 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Aditxt's 14-Day RSI too high?
Aditxt's current 14-Day RSI is 13.94. The Biotechnology industry median 14-Day RSI is 48.89. Aditxt's value of 13.94 is 71.5% below this industry median. Based on the distribution chart, Aditxt ranks #10 out of 1420 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Aditxt's 14-Day RSI compare to AAGH and PKTX?
According to the Biotechnology industry distribution chart, Aditxt ranks #10 out of 1420 companies for 14-Day RSI. This places Aditxt in the top 1% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.89. Aditxt's value of 13.94 is 71.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 48.89, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aditxt's current 14-Day RSI of 13.94 is 71.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Aditxt and its competitors. For the Biotechnology industry, the median 14-Day RSI is 48.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aditxt's current 14-Day RSI is 13.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aditxt stock overvalued right now?
Aditxt (ADTX) has a current 14-Day RSI of 13.94. The current 14-Day RSI is 13.94 and 71.5% below the Biotechnology industry median of 48.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Aditxt (ADTX), the current 14-Day RSI is 13.94 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADTX has been successfully added to your